232 related articles for article (PubMed ID: 38675461)
1. Neurological Adverse Events Related to Immune Checkpoint Inhibitors: A Practical Review.
Zammit F; Seront E
Pharmaceuticals (Basel); 2024 Apr; 17(4):. PubMed ID: 38675461
[TBL] [Abstract][Full Text] [Related]
2. Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management.
Farina A; Villagrán-García M; Honnorat J
Rev Neurol (Paris); 2023 Jun; 179(5):506-515. PubMed ID: 36934022
[TBL] [Abstract][Full Text] [Related]
3. Neurological toxicities associated with immune-checkpoint inhibitors.
Touat M; Talmasov D; Ricard D; Psimaras D
Curr Opin Neurol; 2017 Dec; 30(6):659-668. PubMed ID: 28938341
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
Reynolds KL; Guidon AC
Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
[TBL] [Abstract][Full Text] [Related]
5. Peripheral nervous system adverse events associated with immune checkpoint inhibitors.
Rossi S; Gelsomino F; Rinaldi R; Muccioli L; Comito F; Di Federico A; De Giglio A; Lamberti G; Andrini E; Mollica V; D'Angelo R; Baccari F; Zenesini C; Madia P; Raschi E; Cortelli P; Ardizzoni A; Guarino M
J Neurol; 2023 Jun; 270(6):2975-2986. PubMed ID: 36800019
[TBL] [Abstract][Full Text] [Related]
6. Neurological immune-related adverse events associated with immune checkpoint inhibitors: A review of the literature.
Fan S; Ren H; Zhao L; Yin J; Feng G; Wang J; Guan H
Asia Pac J Clin Oncol; 2020 Dec; 16(6):291-298. PubMed ID: 32893999
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit.
Deharo F; Carvelli J; Cautela J; Garcia M; Sarles C; Maues de Paula A; Bourenne J; Gainnier M; Bichon A
J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233479
[TBL] [Abstract][Full Text] [Related]
8. Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice.
Villagrán-García M; Velasco R
Neurol Sci; 2022 Apr; 43(4):2339-2361. PubMed ID: 35175441
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitors and Neurotoxicity.
Zhao Z; Zhang C; Zhou L; Dong P; Shi L
Curr Neuropharmacol; 2021; 19(8):1246-1263. PubMed ID: 33380303
[TBL] [Abstract][Full Text] [Related]
10. CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review.
Khan E; Shrestha AK; Elkhooly M; Wilson H; Ebbert M; Srivastava S; Wen S; Rollins S; Sriwastava S
J Neurol Sci; 2022 Jan; 432():120089. PubMed ID: 34942546
[TBL] [Abstract][Full Text] [Related]
11. [Distinctive Disease Entity of Neurological Adverse Events Associated with Immune Checkpoint Inhibitors].
Seki M; Suzuki S
Brain Nerve; 2021 Jan; 73(1):35-46. PubMed ID: 33361512
[TBL] [Abstract][Full Text] [Related]
12. Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea.
Hyun JW; Kim KH; Kim SH; Kim HJ
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5583-5589. PubMed ID: 36495331
[TBL] [Abstract][Full Text] [Related]
13. Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies.
Seki M; Kitano S; Suzuki S
Cancer Immunol Immunother; 2022 Apr; 71(4):769-775. PubMed ID: 34515815
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors in Patients with Pre-existing Neurologic Autoimmune Disorders.
Aoun R; Gratch D; Kaminetzky D; Kister I
Curr Neurol Neurosci Rep; 2023 Nov; 23(11):735-750. PubMed ID: 37870664
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of immune checkpoint inhibitor-related neurological adverse events and association with anti-neuronal autoantibodies.
Salim A; Tapia Rico G; Shaikh A; Brown MP
Expert Opin Biol Ther; 2021 Sep; 21(9):1237-1251. PubMed ID: 33645372
[No Abstract] [Full Text] [Related]
16. Neurotoxicities associated with immune checkpoint inhibitor therapy.
Duong SL; Barbiero FJ; Nowak RJ; Baehring JM
J Neurooncol; 2021 Apr; 152(2):265-277. PubMed ID: 33454891
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitor-induced myasthenia gravis, myocarditis, and myositis: A case report.
Basnet A; Sharma NR; Gautam S; Lamichhane S; Kansakar S; Tiwari K; Pokhrel M; Singh S
Clin Case Rep; 2024 Jun; 12(6):e8968. PubMed ID: 38863868
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment.
Psimaras D; Velasco R; Birzu C; Tamburin S; Lustberg M; Bruna J; Argyriou AA
J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S74-S85. PubMed ID: 31393660
[TBL] [Abstract][Full Text] [Related]
19. Neurologic complications of immune checkpoint inhibitors.
Haugh AM; Probasco JC; Johnson DB
Expert Opin Drug Saf; 2020 Apr; 19(4):479-488. PubMed ID: 32126176
[No Abstract] [Full Text] [Related]
20. Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience.
Diamanti L; Picca A; Bini P; Gastaldi M; Alfonsi E; Pichiecchio A; Rota E; Rudà R; Bruno F; Villani V; Galiè E; Vogrig A; Valente M; Zoccarato M; Poretto V; Giometto B; Cimminiello C; Del Vecchio M; Marchioni E
Neurol Sci; 2022 Mar; 43(3):2031-2041. PubMed ID: 34424427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
